Biogen Idec Inc., the world’s largest maker of multiple sclerosis medicines, is on the hunt for new compounds to treat MS and other neurodegenerative diseases, and may purchase companies outright or partner with them, the company’s research chief said.
Their marketing/sales people are among the best around and they pounce on every opportunity to keep the revenue flow coming.
Avonex, even though it is the least expensive of the CRAB's ,has been losing market share for quite some time and we are very aware of the problems associated with Tysabri. The new orals look like they are really going to cut into the market share of Ty although some people feel the nasty side of the orals is yet to make an appearance.
The market share for MS drugs is a battleground with billions of dollars of revenue going to the winner. It's too bad the market success doesn't equate to the efficacy level. But that is another story.